BACKGROUND: The quantity of subarachnoid (SAH) and intraventricular hemorrhage (IVH) occurring in the setting of a ruptured cerebral aneurysm is strongly associated with subsequent complications and poor outcomes. METHODS: We randomly allocated aneurysmal SAH patients with a modified Fisher score of 4, who had been treated withendovascular coil embolization and ventricular drainage, to receive either 2 mg intraventricular tissue plasminogen activator (TPA) every 12 h (maximum 10 mg) or placebo. Computed tomography scans were performed 12, 48, and 72 h after administration. Primary outcomes included feasibility (enrollment and consent rates), safety (assessed by prospectively screening for complications), and rate of intracranial blood clearance (measured using sequential IVH, modified Graeb, and SAH sum scores). Secondary outcomes included angiographic vasospasm, delayed cerebral ischemia, need for ventriculoperitoneal shunting, and 6-month neurological outcomes. RESULTS:Seventy-seven patients were screened, 17 were eligible, and 12 were randomized. The consent rate was 87 %. There were no cases of new intracranial hemorrhage complicating use of TPA. Models fit using generalized estimating equations demonstrated more rapid reduction in IVH volume (p = 0.009), modified Graeb score (p < 0.001), and SAH sum score (p < 0.001) among patients treated with TPA. SAH clearance at 48 h was enhanced by earlier drug administration (p = 0.02). There were no differences in secondary outcomes. CONCLUSIONS:Intraventricular TPA accelerates clearance of SAH and IVH, especially when administered early. A larger-scale clinical trial of intraventricular TPA is feasible, will need to be conducted at multiple centers, and is required to determine whether this practice reduces complications and improves outcomes.
RCT Entities:
BACKGROUND: The quantity of subarachnoid (SAH) and intraventricular hemorrhage (IVH) occurring in the setting of a ruptured cerebral aneurysm is strongly associated with subsequent complications and poor outcomes. METHODS: We randomly allocated aneurysmalSAHpatients with a modified Fisher score of 4, who had been treated with endovascular coil embolization and ventricular drainage, to receive either 2 mg intraventricular tissue plasminogen activator (TPA) every 12 h (maximum 10 mg) or placebo. Computed tomography scans were performed 12, 48, and 72 h after administration. Primary outcomes included feasibility (enrollment and consent rates), safety (assessed by prospectively screening for complications), and rate of intracranial blood clearance (measured using sequential IVH, modified Graeb, and SAH sum scores). Secondary outcomes included angiographic vasospasm, delayed cerebral ischemia, need for ventriculoperitoneal shunting, and 6-month neurological outcomes. RESULTS: Seventy-seven patients were screened, 17 were eligible, and 12 were randomized. The consent rate was 87 %. There were no cases of new intracranial hemorrhage complicating use of TPA. Models fit using generalized estimating equations demonstrated more rapid reduction in IVH volume (p = 0.009), modified Graeb score (p < 0.001), and SAH sum score (p < 0.001) among patients treated with TPA. SAH clearance at 48 h was enhanced by earlier drug administration (p = 0.02). There were no differences in secondary outcomes. CONCLUSIONS: Intraventricular TPA accelerates clearance of SAH and IVH, especially when administered early. A larger-scale clinical trial of intraventricular TPA is feasible, will need to be conducted at multiple centers, and is required to determine whether this practice reduces complications and improves outcomes.
Authors: Rogier P Schade; Janke Schinkel; Freek W C Roelandse; Ronald B Geskus; Leo G Visser; J Marc C van Dijk; Marc C Van Dijk; Joan H C Voormolen; Hans Van Pelt; Ed J Kuijper Journal: J Neurosurg Date: 2006-01 Impact factor: 5.115
Authors: Sang-Bae Ko; H Alex Choi; Amanda Mary Carpenter; Raimund Helbok; J Michael Schmidt; Neeraj Badjatia; Jan Claassen; E Sander Connolly; Stephan A Mayer; Kiwon Lee Journal: Stroke Date: 2011-01-21 Impact factor: 7.914
Authors: Andreas H Kramer; Ivan Mikolaenko; Nathan Deis; Aaron S Dumont; Neal F Kassell; Thomas P Bleck; Barnett A Nathan Journal: Neurosurgery Date: 2010-10 Impact factor: 4.654
Authors: J M Findlay; N F Kassell; B K Weir; E C Haley; G Kongable; T Germanson; L Truskowski; W M Alves; R O Holness; N W Knuckey Journal: Neurosurgery Date: 1995-07 Impact factor: 4.654
Authors: Andreas H Kramer; Craig N Jenne; David A Zygun; Derek J Roberts; Michael D Hill; Jessalyn K Holodinsky; Stephanie Todd; Paul Kubes; John H Wong Journal: J Cereb Blood Flow Metab Date: 2015-04-08 Impact factor: 6.200
Authors: Andreas H Kramer; Craig Jenne; Jessalyn K Holodinsky; Stephanie Todd; Derek J Roberts; Paul Kubes; David A Zygun; Michael D Hill; Caroline Leger; John H Wong Journal: Neurocrit Care Date: 2015-12 Impact factor: 3.210
Authors: Fawaz Al-Mufti; Stephan A Mayer; Gurmeen Kaur; Daniel Bassily; Boyi Li; Matthew L Holstein; Jood Ani; Nicole E Matluck; Haris Kamal; Rolla Nuoman; Christian A Bowers; Faizan S Ali; Hussein Al-Shammari; Mohammad El-Ghanem; Chirag Gandhi; Krishna Amuluru Journal: Neuroradiol J Date: 2021-09-03
Authors: Devin W McBride; Spiros L Blackburn; Kumar T Peeyush; Kanako Matsumura; John H Zhang Journal: Front Neurol Date: 2017-10-23 Impact factor: 4.003
Authors: Thomas S van Solinge; Ivo S Muskens; Vasileios K Kavouridis; William B Gormley; Rania A Mekary; Marike L D Broekman; Omar Arnaout Journal: Neurocrit Care Date: 2020-02 Impact factor: 3.210